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Background: Japan has a high prevalence of adult T-cell leukaemia (ATL), especially in the Kyushu/Okinawa region.
Regional differences in prevalence might cause regional differences in physicians’ experiences and the efficiency of
care-resource use. This study investigated regional differences in the performance of bone marrow transplantation
(BMT), outcome and care-resource use in patients with ATL in Japan.
Methods: This was a cross-sectional study using a Japanese hospital administrative database in 2010, with a
diagnostic-procedure combination/per diem payment system. We examined the association between BMT
performance, resource use, outcomes and region.
Results: We analysed data for 712 subjects of whom 60.5% were Kyushu/Okinawa residents. Significantly more patients
with ATL underwent BMT in Kanto (p = 0.018) and Kansai (p < 0.001) regions compared with the Kyushu/Okinawa
regions. The lengths of hospital stay were longer in Kanto (p = 0.002) and Kansai (p = 0.006) regions than in the
Kyushu/Okinawa region. Total health-care costs were higher in Kanto (p = 0.001) and Kansai (p = 0.005) regions than the
Kyushu/Okinawa region. The risks of in hospital mortality were not significantly different between regions.
Conclusions: There were significant regional differences in BMT performance and resource use within Japan. ATL
prevalence was not related to the performance of BMTs, resource use or outcomes. Factors related to regional
socioeconomics might affect the performance of BMTs and care resource use within Japan.
Keywords: Adult T-cell leukaemia, Regional differences, Bone marrow transplantation, Care-resource, Outcome, Hospital
administrative databaseBackground
Adult T-cell leukaemia (ATL) was initially described by
Takatsuki et al. in 1977 [1]. ATL is characterized by an
increase in mature T cells following the insertion of hu-
man T-lymphotropic virus 1 (HTLV-1) into chromosomal
DNA, and only occurs in HTLV-1 carriers.
HTLV-1 infection is transmitted to newborns by breast
milk from HTLV-1 carrier mothers [2]. ATL occurs in less
than 5% of people with HTLV-I infection, with a mean la-
tency period of more than 30 years [3]. ATL is classified
into four categories [4]. The median survival time ranges
from 3.7 to 6.0 months for the acute and lymphomatous* Correspondence: toshikimaeda1216@gmail.com
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unless otherwise stated.forms, while the median survival is 2 years or more in indo-
lent smouldering and chronic forms [3]. The median sur-
vival time of those treated by chemotherapy was 13 months
[5], thus it is unfavourable compared to other hematologic
malignancies. Accordingly, bone marrow transplantation
(BMT) is a promising therapy associated with long-term
survival [5].
The prevalence of ATL in Japan is one of the highest
worldwide [6]. A national survey conducted in the 1980s
reported that HTLV-1 carriers were concentrated in the
southwest of Japan, with approximately 700 newly diag-
nosed ATL patients per year [7]. Although patients with
ATL have a poor prognosis, the government concluded
that the prevalence of ATL would decrease because of low
infectivity and limited routes of infection, and therefore,
national investigations were discontinued [8]. However,Ltd. This is an Open Access article distributed under the terms of the Creative
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ducted a national survey of HTLV-1 antibodies in newly do-
nated blood samples from 2007 to 2008, which suggested a
figure of approximately 1,080,000 HTLV-1 carriers [9], simi-
lar to that reported previously. In addition, the number of
ATL patients tends to increase as HTLV-1 carriers get older,
and the numbers of patients in urban and suburban areas
have increased [9]. Targeted health care-resource allocation
is therefore urgently required to address the needs of
ATL patients. The government introduced comprehensive
HTLV-1 measures, including prevention, consultation,
specialized institutions, research and development, in
2010 [10].
It is essential to estimate the number of treated patients
and to quantify the efficacy and efficiency of patient care
to improve the health care-delivery system. However, there
have been few studies of the health care-delivery system in
Japan. Regional differences in prevalence of ATL might
also cause regional differences in physicians’ experiences
and the efficiency of care-resource use. Although ATL is
currently incurable, BMT should be available to suitable
patients because as it enhances long-term survival [5].
However, there are regional differences in the use of BMT
for ATL because of cost and the need for experienced phy-
sicians [11].
This study aimed to clarify the regional differences in
the performance of BMT for ATL, and the differences in
prognosis and care-resource use associated with differ-
ent treatment patterns.
Methods
Study design, setting, and participants
This was a cross-sectional study using a Japanese hos-
pital administrative database, the diagnostic-procedure
combination/per diem payment system (DPC/PDPS).
Japanese universal health care insurance is a system that
provides every Japanese citizen with insurance benefits
in cases of disease, injury, death, and childbirth. Every
citizen must belong to one of the social insurance plans
that are composed of three categories: Employee Health
Insurance, District Health Insurance, and Elderly Health
Insurance [12]. The health insurance funds gather pre-
miums from their members and reimburse the costs of
treatment. The reimburse system has long been based
on a fee-for-service (FFS) using a national fee schedule.
The enforcement of the same fee schedule for all insur-
ance plans and almost all providers has maintained
equity and contained costs, and the co-payment rate has
become the same for all, except for elderly people and
children [12].
However health care expenditure in Japan has steadily
increased, and DPC/PDPS was introduced in 2002 to
contain health expenditures [13] and to improve the
quality of care in Japanese care facilities [14].DPC/PDPS has been adopted across the plan, and is
used mainly by research, educational and acute-care fa-
cilities throughout Japan. The DPC programme covers
more than 90% of acute in-patient care in 2007 [13], and
is increasing. The DPC/PDPS includes anonymous charge
data, clinical data and care-process data, which can be
analysed. This study represents the secondary use of DPC/
PDPS collected from June 1st to December 31st 2010,
conducted by MHLW.
Study subjects were patients admitted to a hospital for
chemotherapy, whose primary diagnosis was classified as
‘C915’, corresponding to ATL in ICD10. Chemotherapy
was defined as the use of chemotherapeutic agents used
by ‘quality indicators programs’ in Japanese national hos-
pitals. The demographical data were obtained from re-
lated bureaus. Data related to BMT was obtained from
the Japan Society for Hematopoietic Stem Cell Trans-
plantation [15]. The outline for this study followed the
STROBE guidelines [16] and was approved by the ethics
committee of the University of Occupational and Envir-
onmental Health in Kitakyushu, Fukuoka, Japan.
Definition of variables
We used population, population density and proportions
of aging of each region as demographic measures. We
identified the number of hospitals, number of hospitals
per inhabitants, number of beds, number of beds per
inhabitants, number of DPC hospitals, number of DPC
hospitals per inhabitants, number of beds in DPC hospi-
tals, number of beds in DPC hospitals per inhabitants,
number of academic hospitals, number of academic hos-
pitals per inhabitants, total medical expenditures, and
total medical expenditures per capita as a measure of
care delivery systems in Japan. The number of BMT
teams, BMT team densities [11], total number of allo-
geneic BMTs, BMT rate [11] and number of BMTs per
team was used as a measure of care resources of BMT
delivery in Japan.
The variables used for analyses were gender, age, pa-
tient’s residence area, route of admission, hospital function,
Charlson’s comorbidity index (CCI) [17], performance of
BMT, in hospital mortality (IHM), length of stay (LOS)
and total hospital charge (TC).
Age was categorized as <65, and ≥65 years. Prefectures
and regions (‘Hokkaido/Tohoku’, ‘Kanto’, ‘Chubu, Kansai’,
‘Chugoku/Shikoku’, and ‘Kyushu/Okinawa’) were defined
according to the general rule in Japan (Figure 1). The
route of admission was categorized as ‘elective’ or ‘urgent’.
Hospital function was classified as ‘academic hospital’, in-
cluding 80 university hospitals and two national centres,
or ‘community hospital’. A CCI score of 0 indicated no co-
morbidities, and a score ≥1indicated the presence of co-
morbidities, excluding ATL as the primary neoplasm. The








Figure 1 Definition of regions in Japan.
Maeda et al. BMC Health Services Research 2014, 14:337 Page 3 of 8
http://www.biomedcentral.com/1472-6963/14/337standardized fee-for-service payment system. We classified
patients who received sequential chemotherapy and BMT
in the BMT group.
We used IHM as index of outcome and TC and LOS
as indices of care resource use. Although IHM was not
regarded as an endpoint in general, we assumed that
skilled experts could identify successful BMT compared
with non-skilled individuals, thus in hospital mortality
might be lower. TC (@JPY 100/USD) billed during ad-
mission was used as a proxy for cost [18]. In Japan, hos-
pital charges are determined by the national uniform fee
schedule. In this study, TC included physician fees, in-
strument costs, laboratory or imaging test costs, and ad-
ministration fees.
Statistical procedures
Data were analysed using χ2 tests for categorical vari-
ables and Kruskal-Wallis for continuous variables. Lo-
gistic regression analysis was used to determine the
relationships between BMT and region, age, gender,
route of admission, hospital function and comorbidity.
The relationships between IHM and region, age, gender,
BMT, route of admission, hospital function and comor-
bidity were determined by logistic regression analysis,
and multiple linear regression analysis was used to
quantify the effects of region, age, gender, BMT, IHM,
route of admission, hospital function and comorbidity
on LOS and TC. The distributions of both LOS and
TC were right-skewed and these values were therefore
log10-transformed in this model. The reference region
for odds ratios (ORs) was Kyushu/Okinawa, because
it had the highest prevalence rate of ATL. All statis-
tical analyses were performed using PASW Statistics
18 (SPSS Inc., Chicago, IL, USA). All reported p values
were two tailed, and the level of significance was set
at 0.05.Results
The characteristics of each region are shown in Table 1.
The density of inhabitants was concentrated in the
Kanto and Kansai regions. Densities of hospitals, hos-
pital beds, DPC hospitals and DPC hospital beds tended
to be higher in the Chugoku/Shikoku and Kyushu/Okinawa
regions than in the other regions examined. The densities
of academic hospitals were higher in the Kanto region.
The medical expenditures per capita were lower in the
Kanto region. The team densities were lower in Kanto and
higher in the Chugoku/Shikoku regions. The BMT rate
was higher in the Kansai and Chugoku/Shikoku regions.
The number of BMTs per team was highest in the Kanto
and Kansai regions. The result of patient travelling to visit
hospitals is shown in Table 2. Almost all patients were
treated within their own region.
The distribution of subjects by region is shown in
Table 3. There were a total of 712 subjects, of whom
60.5% were Kyushu/Okinawa residents. There were sig-
nificant relationships between region and gender, age,
hospital functions and therapy. Subjects in the Kanto
and Chubu regions tended to be younger than those in
the Kyushu/Okinawa region. The proportions of academic
hospitals tended to be higher in the Kanto and Chugoku/
Shikoku regions compared with Kyushu/Okinawa. The
proportions of patients treated with BMT tended to be
higher in the Kanto and Kansai regions compared with the
Kyushu/Okinawa region.
The results of multivariate regression analyses are
shown in Table 4. The variables significantly related
to performance of BMT were living in the Kanto and
Kansai regions (adjusted OR (AOR) 2.88 [1.20–6.89],
AOR 6.30 [2.98–13.32], respectively, reference = Kyushu/
Okinawa region), age (≥65; AOR 0.10 [0.04–0.24], refer-
ence = <65 years), academic hospital (AOR 1.93 [1.03–
3.62], reference = community hospital) and comorbidity
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35.4 2388.4 50 33.7 344 231.79 6.9
Kanto 83.2 1953.8 102 23.9 1055 247.63 10.3
Chubu 50.2 2131.9 78 33.1 458 194.31 5.9
Kansai 50.0 2390.4 78 37.3 625 299.00 8.0
Chugoku/
Shikoku
30.9 2679.0 57 49.4 344 298.12 6.0
Kyushu/
Okinawa
30.8 2728.9 60 41.1 398 272.66 6.6
DPC: Diagnosis Procedure Combination, LOS: Length of stay, BMT: Bone marrow transplantation.
Table 2 Matrix of patient travelling
Hospital address
Hokkaido/Tohoku Kanto Chubu Kansai Chugoku/Shikoku Kyusuhu/Okinawa
Total
N (%) N (%) N (%) N (%) N (%) N (%)
Patient residence
Hokkaido/Tohoku 67 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 67
Kanto 0 (0.0) 130 (99.2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.3) 132
Chubu 0 (0.0) 0 (0.0) 74 (98.7) 0 (0.0) 0 (0.0) 2 (0.3) 76
Kansai 0 (0.0) 0 (0.0) 1 (1.3) 174 (99.4) 2 (2.3) 0 (0.0) 177
Chugoku/Shikoku 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 84 (97.7) 0 (0.0) 84
Kyushu/Okinawa 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.6) 0 (0.0) 652 (99.4) 654
Total 67 (100.0) 131 (100.0) 75 (100.0) 175 (100.0) 86 (100.0) 656 (100.0) 1190
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Table 3 Distribution and characteristics of subjects by region
Region
Hokkaido/






Shikoku (N = 55)
Kyushu/Okinawa
(N = 431) p value
Gender
Male (%) 17 (53.1) 41 (66.1) 26 (57.8) 33 (37.9) 29 (52.7) 219 (50.8)
0.028
Female (%) 15 (46.9) 21 (33.9) 19 (42.2) 54 (62.1) 26 (47.3) 212 (49.2)
Age
<65 (%) 13 (40.6) 40 (64.5) 24 (53.3) 48 (55.2) 28 (50.9) 184 (42.7)
0.012
≧65 (%) 19 (59.4) 22 (35.5) 21 (46.7) 39 (44.8) 27 (49.1) 247 (57.3)
Route of admission
Elective (%) 27 (84.4) 51 (82.3) 39 (86.7) 75 (86.2) 48 (87.3) 383 (88.9)
0.740
Urgent (%) 5 (15.6) 11 (17.7) 6 (13.3) 12 (13.8) 7 (12.7) 48 (11.1)
Hospital function
Community (%) 27 (84.4) 33 (53.2) 31 (68.9) 72 (82.8) 32 (58.2) 345 (80.0)
<0.001
Academic (%) 5 (15.6) 29 (46.8) 14 (31.1) 15 (17.2) 23 (41.8) 86 (20.0)
Comobidity
Absent (%) 18 (56.3) 36 (58.1) 25 (55.6) 50 (57.5) 35 (56.3) 260 (60.3)
0.950
Present (%) 14 (43.8) 26 (41.9) 20 (44.4) 37 (42.5) 20 (43.8) 171 (39.7)
Therapy
Chemotherapy (%) 30 (93.8) 51 (82.3) 40 (88.9) 66 (75.9) 53 (96.4) 408 (94.7)
<0.001
BMT (%) 2 (6.3) 11 (17.7) 5 (11.1) 21 (24.1) 2 (3.6) 23 (5.3)
Outcome
In hospital mortality (IQR) 8 (25.0) 8 (12.903) 7 (15.6) 15 (17.2) 13 (23.6) 91 (21.1) 0.519
0.519 Length of stay (IQR) 40 (59.0) 50 (61.0) 39 (50.0) 48 (63.0) 35 (34.0) 32 (47.0) <0.001a
0.001a Total cost ($) (IQR) 1497.7 (1944.6) 2082.8 (5244.6) 1594.2 (3221.1) 1761.2 (5612.5) 1282.2 (2126.0) 1304.6 (1779.2) <0.001a
aby Kruskal-Wallis test, other p values by chi-square test, BMT: Bone marrow transplantation.
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absent).
There were no relationships between performance of
BMT and region or IHM. The variables related to IHM
were age (≥65; AOR 1.57 [1.03–2.38], reference = <65) and
urgent admission (AOR 2.43 [1.46–4.04], reference = elect-
ive admission), academic hospitals (AOR 0.54 [0.32–0.91],
reference = community hospitals) and BMT (AOR 4.61
[2.37–8.97], reference = BMT not performed).
Related to logLOS, Kanto (standardized partial regres-
sion coefficient (β) 0.11 [0.13–0.59] and Kansai (β 0.10
[0.08–0.47]) regions had significantly longer LOS than
that of the Kyushu/Okinawa region.
Other variables significantly related to logLOS were
urgent admission (β 0.11 [0.10–0.48], reference = elective
admission), BMT (β 0.24 [0.55–1.02], reference = BMT
not performed) and IHM(β 0.27 [0.47–0.78], reference =
no in hospital mortality).
Kanto (β 0.10 [0.15–0.61]) and Kansai (β 0.09 [0.09–
0.48]) regions also had significantly higher logTC than
that of the Kyushu/Okinawa region. Other variables re-
lated to logTC were urgent admission (β 0.13 [0.23–0.60],reference = elective admission), academic hospital (β 0.12
reference = community hospital), BMT (β 0.45 [1.48–
1.95], reference = BMT not performed) and IHM (β 0.32
[0.71–1.02], reference = no in hospital mortality).
Discussion
This study clarified the association between residence re-
gion and the proportion of patients with ATL who re-
ceived BMT, IHM, LOS and TC. There were significant
regional differences in performance of BMT as Kanto and
Kansai regions had significantly higher rates of BMT per-
formance. Although the Kyushu/Okinawa regions had a
high prevalence of ATL, a lower proportion of patients
were treated with BMT. Additionally, the Kanto and Kan-
sai regions had high care resource use, while there was no
significant difference in IHM between regions.
Previous studies in Western countries reported re-
gional differences in the use of BMT were related to the
prevalence of related diseases [11], per capita gross na-
tional income and per capita health care expenditures as
economic factors, and the availability of BMT teams as
care resources [19,20]. However, the current study found
Table 4 Results of multivariate regression analyses
BMT IHM LogLOS LogTC
AOR 95% CI p AOR 95% CI p β 95% CI p β 95% CI p
Region
Hokkaido/Tohoku 1.79 [0.36-8.92] 0.478 1.16 [0.50-2.73] 0.726 0.03 [-0.17-0.43] 0.400 0.02 [-0.19-0.14] 0.475
Kanto 2.88 [1.20-6.89] 0.018 0.49 [0.22-1.13] 0.094 0.11 [0.13-0.59] 0.002 0.10 [0.15-0.61] 0.001
Chubu 2.35 [0.77-7.15] 0.133 0.65 [0.27-1.55] 0.327 0.02 [-0.19-0.32] 0.606 0.01 [-0.23-0.28] 0.838
Kansai 6.30 [2.98-13.32] <0.001 0.59 [0.31-1.13] 0.111 0.10 [0.08-0.47] 0.006 0.09 [0.09-0.48] 0.005
Chugoku/Shikoku 0.42 [0.09-1.89] 0.256 1.38 [0.69-2.77] 0.369 -0.01 [-0.26-0.21] 0.818 0.00 [-0.24-0.23] 0.961
Kyushu/Okinawa reference reference reference reference
Gender
Male reference reference reference reference
Female 0.80 [0.44-1.46] 0.468 0.69 [0.47-1.01] 0.058 0.02 [-0.09-0.16] 0.606 0.03 [-0.07-0.18] 0.377
Ages
<65 reference reference reference reference
≥65 0.10 [0.04-0.24] <0.001 1.57 [1.03-2.38] 0.035 -0.02 [0.16-0.10] 0.637 -0.04 [-0.21-0.05] 0.245
Route of admission
Elective reference reference reference reference
Urgent 0.26 [0.06-1.17] 0.079 2.43 [1.46-4.04] 0.001 0.11 [0.10-0.48] 0.002 0.13 [0.23-0.60] <0.001
Hospital function
Community reference reference reference reference
Academic 1.93 [1.03-3.62] 0.039 0.54 [0.32-0.91] 0.021 0.04 [-0.06-0.24] 0.246 0.12 [0.14-0.44] <0.001
Comobidity
Absent reference reference reference reference
Present 0.19 [0.09-0.43] <0.001 0.89 [0.60-1.33] 0.569 -0.02 [-0.16-0.09] 0.605 0.01 [-0.11-0.15] 0.755
Procedure
BMT - 4.61 [2.37-8.97] <0.001 0.24 [0.55-1.02] >0.001 0.45 [1.48-1.95] <0.001
Outcomes
IHM - - 0.27 [0.47-0.78] <0.001 0.32 [0.71-1.02] <0.001
Goodness of fit 0.738a 0.801a 0.187b 0.413b
IHM: In hospitality, LOS: Length of stay, TC: Total charge, CTx: Chemotherapy, BMT: Bone marrow transplantation.
AOR: Adusted odds ratio, β: Standardized coefficient.
a:Hosmer-Lemeshow test, bCoefficient of determination.
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ATL and the performance of BMT in Japan. Regarding
economic factors, the health care expenditure per capita
in the Kanto and Kansai regions, where higher numbers
of BMTs were performed, was no higher than those of
other regions. Reasons for the relatively lower health
care expenditures observed could be age structure, that
is, a lower proportion of elderly individuals in the Kanto
and Kansai regions leading to lower health care expend-
iture, especially as there was no association between
health care expenditure and performing BMT. However,
there might be a relationship between household income
and BMT, as demographic data showed that Kanto and
Kansai regions were densely inhabited, and that their in-
comes seemed to be higher. There was no relationship be-
tween care resources, including the number of hospitalsor BMT team density and performing BMT, which was in
contrast to prior findings. However, the discrepancy be-
tween high numbers of BMTs performed and equivalent
care resources in Kanto and Kansai regions might be at-
tributed to the type of health care delivery system in Japan.
The health care plan determined by local government in
Japan was revised 5 years ago. The aim of the health care
plan is to allocate health care resources equally in Japan.
However, it focused on quantity rather than quality, in
general. Thus, care resources in the Kanto and Kansai re-
gions were almost equivalent to other regions. However,
the number of BMTs performed per team was higher in
the Kanto and Kansai regions. Thus, the efficiency of care
might be superior in the Kanto and Kansai regions, al-
though the quantity of care resources was equivalent be-
tween all regions.
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not lead to lower IHM. Although many studies have in-
vestigated relationships between care resource use and
outcomes, there is still no definitive evidence. IHM used
in this study were not relevant as outcome measures;
outcome measures used in hemato-oncologic research
are generally overall survival [21], or day 100 mortality,
especially for BMT [22]. Another explanation might be
there simply was no association between care resource
and outcome. An additional potential reason might be
diminishing health values as expenditure increases [23].
Further studies are required to determine definitive
information.
An important finding of the current study was that the
care system in Japan should enhance consolidation ra-
ther than increase quantity. Furthermore, the health care
delivery system should be assessed by quality rather than
quantity in Japan.
Finally, in Japan there has been no national epidemio-
logic research for approximately 10 years, despite the high
prevalence of ATL. Therefore, it is important to monitor
the prevalence of ATL to enable policy makers to plan
preventive strategies. DPC/PDPS data or the national
medical claims database could facilitate epidemiologic re-
search, and we suggest that these databases should be used
more widely.
There were some limitations to the methodology and
interpretation of the current study. The data used were
only gathered over a 7-month period in 2010, and there-
fore might not be fully representative. Another potential
limitation is that DPC/PDPS data could not provide
follow-up data for subjects, because the only available
outcome was IHM. In addition, we were unable to dis-
criminate between myeloablative and non-myeloablative
BMT using the current data. Furthermore, we could not
obtain data related to primary evaluation, prevalence of
disease, transplant rate and proportion of patients with
transplantation that would allow a comparison of ATL
with other diseases with homogeneous distribution in
Japan.
Conclusions
There were significant regional differences in the perform-
ance of BMTs and resource use within Japan. ATL preva-
lence was not related to BMT performance, resource use
or outcomes. Factors related to regional socioeconomics
might affect the performance of BMTs and care resource
use within Japan.
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